Bristol-Myers Squibb (BMY) Tops Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq climbs over 1% as SpaceX, Super Micro improve AI sentiment
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Nvidia’s Huang highlights AI benefits in Berlin speech amid wider European tour
- AI bubble about to burst? Not yet, Yardeni says
Tweet
Share
E-mail
Get Alerts BMY Hot Sheet
Price: $60.81 -1.41%
EPS Growth %: -33.1%
Financial Fact:
Cost of products sold: 1.31B
Today's EPS Names:
OMID, BCML, CZNC, More
EPS Growth %: -33.1%
Financial Fact:
Cost of products sold: 1.31B
Today's EPS Names:
OMID, BCML, CZNC, More
Join SI Premium – FREE
Bristol-Myers Squibb (NYSE: BMY) reported Q4 EPS of $1.82, $0.09 better than the analyst estimate of $1.73. Revenue for the quarter came in at $11.4 billion versus the consensus estimate of $11.21 billion.
GUIDANCE:
Bristol-Myers Squibb sees FY2023 EPS of $7.95-$8.25, versus the consensus of $8.00. Total revenues are expected to increase by approximately 2% at reported rates and approximately 2% excluding foreign exchange.
For earnings history and earnings-related data on Bristol-Myers Squibb (BMY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix shares fall over 5% premarket on soft current-quarter revenue guidance
- Alaska Air Group (ALK) Tops Q3 EPS by 8c; offers guidance
- OFG Bancorp (OFG) Tops Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
